Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FLGC Flora Growth	$20.77 +0.3%	$23.11	$15.15 ▼ $82.29	$12.05M	1.97	6,571 shs	7,319 shs
GELS Gelteq	$1.25 -3.7%	$1.65	$0.77 ▼ $5.50	$11.82M	N/A	1.17 million shs	24,370 shs
GOVX GeoVax Labs	$0.75 +0.1%	$0.74	$0.43 ▼ $5.28	$11.87M	3.27	984,588 shs	276,064 shs
UBX UNITY Biotechnology	$0.18 -40.4%	$0.43	$0.20 ▼ $3.10	$3.08M	0.92	284,137 shs	3.73 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FLGC Flora Growth	-2.07%	+9.64%	-13.83%	-13.85%	-47.17%
GELS Gelteq	-2.26%	+3.17%	-30.67%	-16.67%	+129,999,900.00%
GOVX GeoVax Labs	-1.76%	-0.71%	-0.93%	-28.82%	-85.11%
UBX UNITY Biotechnology	0.00%	0.00%	0.00%	-73.68%	-89.28%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FLGC Flora Growth	3.3556 of 5 stars	3.5	5.0	0.0	0.0	3.8	0.8	0.6
GELS Gelteq	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GOVX GeoVax Labs	1.978 of 5 stars	3.5	2.0	0.0	0.0	2.7	0.0	0.6
UBX UNITY Biotechnology	2.0359 of 5 stars	3.2	0.0	0.0	4.7	0.0	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FLGC Flora Growth	3.00	Buy	$93.00	347.76% Upside
GELS Gelteq	0.00	N/A	N/A	N/A
GOVX GeoVax Labs	3.00	Buy	$8.50	1,040.02% Upside
UBX UNITY Biotechnology	2.33	Hold	$2.33	1,203.54% Upside

Current Analyst Ratings Breakdown

Latest UBX, FLGC, GOVX, and GELS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
8/5/2025	FLGC Flora Growth	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$30.00
7/29/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
7/17/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/16/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FLGC Flora Growth	$59.51M	0.20	N/A	N/A	$6.95 per share	2.99
GELS Gelteq	N/A	N/A	N/A	N/A	$1.30 per share	N/A
GOVX GeoVax Labs	$6.14M	1.93	N/A	N/A	$0.18 per share	4.14
UBX UNITY Biotechnology	N/A	N/A	N/A	N/A	$0.39 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FLGC Flora Growth	-$15.91M	-$34.38	N/A	N/A	N/A	-24.86%	-261.57%	-48.06%	11/12/2025 (Estimated)
GELS Gelteq	-$2.33M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
GOVX GeoVax Labs	-$24.99M	-$2.01	N/A	N/A	N/A	-403.88%	-408.80%	-279.89%	11/11/2025 (Estimated)
UBX UNITY Biotechnology	-$25.99M	-$1.62	N/A	N/A	N/A	N/A	-246.82%	-58.81%	N/A

Latest UBX, FLGC, GOVX, and GELS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/1/2025	Q2 2025	FLGC Flora Growth	-$0.06	-$0.11	-$0.05	-$0.11	$11.77 million	$14.80 million
7/28/2025	Q2 2025	GOVX GeoVax Labs	-$0.41	-$0.35	+$0.06	-$0.35	$0.37 million	$0.85 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FLGC Flora Growth	N/A	N/A	N/A	N/A	N/A
GELS Gelteq	N/A	N/A	N/A	N/A	N/A
GOVX GeoVax Labs	N/A	N/A	N/A	N/A	N/A
UBX UNITY Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FLGC Flora Growth	0.50	0.96	0.61
GELS Gelteq	N/A	0.79	N/A
GOVX GeoVax Labs	N/A	2.03	2.03
UBX UNITY Biotechnology	N/A	1.95	1.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FLGC Flora Growth	36.01%
GELS Gelteq	N/A
GOVX GeoVax Labs	6.09%
UBX UNITY Biotechnology	29.49%

Insider Ownership

Company	Insider Ownership
FLGC Flora Growth	12.56%
GELS Gelteq	N/A
GOVX GeoVax Labs	1.20%
UBX UNITY Biotechnology	5.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FLGC Flora Growth	280	580,000	506,000	Not Optionable
GELS Gelteq	N/A	9.44 million	N/A	N/A
GOVX GeoVax Labs	10	15.93 million	15.73 million	Not Optionable
UBX UNITY Biotechnology	60	17.21 million	16.21 million	Optionable

UBX, FLGC, GOVX, and GELS Headlines

Recent News About These Companies

Unity Stock Crashes Nearly 50% After Nasdaq Delisting Notice

June 30, 2025 | finance.yahoo.com

Unity Biotechnology stock plunges after Nasdaq delisting notice

June 30, 2025 | za.investing.com

Unity Biotechnology Inc News (UBX) - Investing.com

June 26, 2025 | investing.com

UBX Unity Biotechnology, Inc. - Seeking Alpha

June 24, 2025 | seekingalpha.com

HC Wainwright & Co. Downgrades Unity Biotechnology (UBX)

May 28, 2025 | msn.com

Unity Biotechnology (UBX) was downgraded to a Hold Rating at Mizuho Securities

May 18, 2025 | theglobeandmail.com

Bay Area biotech company Unity lays off every single worker, including CEO

May 6, 2025 | msn.com

Bay Area biotech company Unity, once worth $700M, lays off entire remaining workforce

May 5, 2025 | msn.com

South San Francisco biotech company lays off entire workforce, including CEO

May 5, 2025 | msn.com

Unity disbands workforce as it searches for strategic path forward, while Mammoth cuts 24 roles

May 5, 2025 | fiercebiotech.comF

UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting

May 1, 2025 | globenewswire.com

NEJM Evidence publishes results from Phase 2 BEHOLD study of UBX1325

April 25, 2025 | ophthalmologytimes.comO

UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates

April 22, 2025 | globenewswire.com

Unity Biotechnology price target lowered to $4 from $8 at H.C. Wainwright

March 26, 2025 | markets.businessinsider.com

Unity Biotechnology price target lowered to $4 from $6 at Chardan

March 26, 2025 | markets.businessinsider.com

Unity Biotechnology announces results from ASPIRE Phase 2b study in DME

March 25, 2025 | markets.businessinsider.com

Unity reports topline outcomes from trial of diabetic macular oedema therapy

March 25, 2025 | msn.com

UNITY Biotechnology tanks on mixed results for eye disease drug

March 25, 2025 | thepharmaletter.comT

UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study

March 25, 2025 | zacks.com

UNITY Biotechnology Shares Drop 33% After Phase 2b Trial Data on UBX1325 in Diabetic Macular Edema

March 24, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

UBX, FLGC, GOVX, and GELS Company Descriptions

Flora Growth NASDAQ:FLGC

$20.77 +0.07 (+0.34%)

Closing price 03:57 PM Eastern

Extended Trading

$19.80 -0.97 (-4.67%)

As of 04:13 PM Eastern

Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.

Gelteq NASDAQ:GELS

$1.25 -0.05 (-3.69%)

As of 03:59 PM Eastern

Gelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.

GeoVax Labs NASDAQ:GOVX

$0.75 +0.00 (+0.15%)

As of 04:00 PM Eastern

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

UNITY Biotechnology NASDAQ:UBX

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time